25th EADV Congress day 3 highlight: Treating additional manifestations of psoriasis

25th EADV Congress day 3 highlight: Treating additional manifestations of psoriasis


At the EADV this year, there’s been a renewed
emphasis on looking at trials of special forms of psoriasis to see if our new therapeutics
have an impact on these diseases. For example, there are clinical trials specifically
with secukinumab for scalp psoriasis and secukinumab for the very, very difficult to treat palmar
plantar pustulosis. Both of these trials suggest that this medication
works quite nicely. The palmar plantar pustulosis still remains
a challenge for physicians using any medication. Additionally, studies of classical palmar
plantar psoriasis with ixekizumab in a subanalysis of the Phase 3 clinical trial shows a high
level of efficacy. And looking at nail disease which is again,
very, very difficult to treat with secukinumab, shows some quite remarkable results in some
of the patients–the clearing of very, very severe disease in multiple patients. We’re hopeful that they’ll be renewed inquiry
and prolonged inquiry into how our new medications affect these special forms of psoriasis that
have such a devastating impact on our patients.

Leave a Reply

Your email address will not be published. Required fields are marked *